Compositions containing virus-like particles as immunopotentiators administered through the mucosa
US7374766B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 1, 1999 |
| Grant date | May 20, 2008 |
| Priority date | — |
| Expiry date | Dec 1, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2730/10134
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is related to the branch of medicine, particularly to the new formulations of vaccine antigens.The technical objective pursued with the present invention is, precisely, the development of formulations that are able to enhance the immune response to mucosally administered antigens, minimising the number of compounds in the formulation and generating strong mucosal and systemic responses through a synergic interaction between the antigens in the formulation.These formulations enable: a) to broaden the spectrum of the anti-hepatitis B immune response, containing as main compounds HBsAg and HBcAg, b) to enhance the response against HBsAg with a viral nucleocapsid c) to generate combined vaccines through the mucosal route with HBsAg as a central antigen. Stabilizers and preservatives can be introduced.The formulations of this invention can be applied in the pharmaceutical industry as human or veterinary vaccine formulations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.